Medicare targets popular weight loss drugs Ozempic, Wegovy

Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.
Medicare announces plan to negotiate prices of diabetes, weight loss drugs
WASHINGTON — Medicare officials announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy, further complicating big decisions the Trump administration will have to make about how to cover the medications.
Ozempic, Wegovy and other drugs are among 15 selected for Medicare's price negotiations
Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare's list of medications that will be negotiated directly between the government and drug manufacturers, the Biden administration said Friday.
Medicare announces 15 new drugs up for price negotiations, including Ozempic
The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, which includes Ozempic.
Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
The Biden administration moved Friday to negotiate the prices Medicare pays for the blockbuster weight-loss drugs Ozempic and Wegovy, medications costing the massive government health program billions of dollars a year.
Biden administration adds 15 drugs to Medicare price negotiation list
The price negotiations for the additional 15 drugs selected will be handled by the incoming Trump administration and, if deals are reached, almost assure billions of dollars in savings for taxpayers.
Feds add Wegovy, Ozempic to list of drugs planned for Medicare price negotiations
Wegovy, Ozempic added to list of drugs where the federal government will try winning discounts from manufacturers.
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.
Explainer: What Wegovy's inclusion in Medicare price negotiation means for patients, company
The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027, which includes Novo Nordisk's blockbuster weight-loss drug Wegovy. Here's
Ozempic among drugs targeted in upcoming Medicare price negotiations
Novo Nordisk’s blockbuster diabetes and weight-loss drugs Ozempic and Wegovy are among a group of 15 drugs set to be affected by the next round of US government price negotiations by Medicare. The group of drugs accounted for about $41bn in annual spending by Medicare,
Mounjaro vs. Ozempic: Which One Is Best for Me to Try for Weight Loss in 2025?
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
Meet ‘Super’ Ozempic: Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
NOLA.com3d
Can weight loss drugs curb alcohol addictions? New research looks at the possibility.
Can weight loss drugs curb alcohol addictions? This Louisiana doctor is keeping an eye on new findings and emerging research.
Medscape3d
New Weight Loss Drugs May Fight Obesity-Related Cancer, Too
Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.